

****PLEASE NOTE: ALL BUPRENORPHINE OR BUPRENORPHINE/NALOXONE REQUESTS MUST BE SUBMITTED VIA FAX or ePA.**

Member Information (REQUIRED)			Prescriber Information (REQUIRED)		
Member Name:			Provider Name:		
Insurance ID#:			NPI#:	X-DEA#:	
Date of Birth:			DEA#:	Specialty:	
Street Address:			Office Phone:	Office Fax:	
City:	State:	Zip:	Supervising Physician and DEA# (if applicable):		
Phone:			Office Street Address:		
			City:	State:	Zip:
			Is the prescriber a TennCare provider with a Medicaid ID? <input type="checkbox"/> Yes <input type="checkbox"/> No		
			Is the prescriber a single-patient contract holder for this patient? <input type="checkbox"/> Yes <input type="checkbox"/> No		

*****To be in the TennCare Buprenorphine Enhanced Supportive Medication-Assisted Recovery and Treatment (BESMART), the provider must have a separate BESMART contract with the Managed Care Organizations (MCOs).*****

PLEASE READ: Nurse Practitioners (NP) and Physician Assistants (PA) seeking to prescribe buprenorphine-containing products to TennCare members must be a TennCare BESMART Provider. Requests from NPs and PAs not contracted in the BESMART Network will be denied. Please answer the following questions to determine if you are eligible to prescribe these medications for TennCare patients:

- What is your provider type?
 Physician (MD, DO) Nurse Practitioner (NP) Physician Assistant (PA)
- Are you contracted with at least one TennCare MCO as a BESMART Network Provider **and** attested to the Program Description?
 Yes No
 - If **YES**, provider is eligible to prescribe buprenorphine medications. Complete the BESMART network section of the prior authorization form.
 - If **NO**, only physicians are eligible to prescribe. Complete the non-BESMART Network section of the form.

IF YES TO THE QUESTION ABOVE:

TennCare BESMART Network Provider ONLY	
Requested Buprenorphine Product	
Preferred	Non-Preferred
<input type="checkbox"/> Bunavail [®]	<input type="checkbox"/> Buprenorphine mono
<input type="checkbox"/> Buprenorphine/naloxone SL Tablet	<input type="checkbox"/> Other: _____
<input type="checkbox"/> Buprenorphine/naloxone Film	Indication: <input type="checkbox"/> Pregnancy/breastfeeding <input type="checkbox"/> Allergy to naloxone (documentation required) <input type="checkbox"/> Other: _____ Complete Question 4 on Page 2.
1. Requested Strength: _____	
2. Number of Units/Day: _____	
3. Rx Directions: _____	
4. Total Number of Units/Rx: _____	

IF NO TO THE QUESTION ABOVE:

All Other TennCare Prescribers	
Requested Buprenorphine Product	
Preferred	Non-Preferred
<input type="checkbox"/> Bunavail [®]	<input type="checkbox"/> Buprenorphine mono
<input type="checkbox"/> Buprenorphine/naloxone SL Tablet	<input type="checkbox"/> Other: _____
	Indication: <input type="checkbox"/> Pregnancy <input type="checkbox"/> Allergy to naloxone (documentation required) <input type="checkbox"/> Other: _____ Complete Question 15 on page 5.
1. Requested Strength: _____	
2. Number of Units/Day: _____	
3. Rx Directions: _____	
4. Total Number of Units/Rx: _____	

TennCare BESMART Network Provider

NOTE: For induction and stabilization/maintenance therapy phases in adults, TennCare covers up to 8.4 mg of buprenorphine per day when product selected is Bunavail®, and up to 16 mg per day when product selected is Suboxone®, Subutex®, or generic equivalents.

Based on the information above, will the recipient be using a larger daily dose/quantity than TennCare covers? Yes No *If Yes, please answer question 5 below.*

1. Are you a contracted with at least one TennCare MCO as a BESMART provider, attested to the MAT Program Description and have a valid TennCare ID? Yes No
If No, skip to the "All other prescribers" section.
2. Diagnosis: Treatment of opiate addiction/ODU Other: _____
3. Will buprenorphine be used for treatment of depression or pain? Yes No
4. If requesting a non-preferred agent, please submit documentation of allergy to inactive ingredient in preferred product that is not in the requested product and any other information pertinent to this prior authorization request:

IF REQUESTING ABOVE THE QUANTITY LIMIT for buprenorphine containing products, complete question 5.

5. Please provide a clinical rationale for the requested dosage with one of the following reasons:
 - Pregnant patients confirmed by provider attestation.
 - Postpartum patients for a period of 12 months from delivery date. *Please provide medical records or insurance claim.*
 - Recent intravenous drug users confirmed by prescriber attestation and a positive urine drug screen.
 - Current users receiving greater than 50 mg of methadone for OUD treatment transitioning to buprenorphine agonist therapy. *Please provide paid claims data from the enrollee's health insurer, provider attestation, or medical records.*
 - Current users of 16 mg to 24 mg per day of buprenorphine. *Please provide paid claims data from enrollee's previous health insurer.*
 - For one (1) year from the effective date of Rule 1200-13-13-.15, a member who does not qualify under the criteria of this part but receives greater than sixteen (16) mg per day of buprenorphine as demonstrated by the controlled substance monitoring database shall be eligible to receive a maximum daily dose of twenty-four (24) mg.

*****If the most recent prior authorization approval for buprenorphine/naloxone or buprenorphine was requested by a different prescriber, please ensure transfer of care has occurred. *****

Prescriber Signature (Required)

By signature, the prescriber attested to the BESMART Program Description and requirements (e.g. check CSMD, provide care coordination, ensure access to counseling services)

Date

Fax this form to: 1-866-434-5523
Phone: 1-866-434-5524

OptumRx will provide a response within 24 hours upon receipt.

IMPORTANT! Nurse Practitioners and Physician Assistants not contracted in the BESMART Provider Network are not eligible to prescribe buprenorphine medications. Requests received will be denied.

All Other TennCare Prescribers

(Excluding Nurse Practitioners and Physician Assistants)

NOTE: For induction therapy in adults, TennCare covers up to 8.4 mg of buprenorphine per day when product selected is Bunavail®, and up to 16 mg per day when product selected is Suboxone®, Subutex®, or generic equivalents for 6 months. During stabilization/maintenance phases, coverage is reduced to a max of 4.2 mg of buprenorphine per day for Bunavail®, and 8 mg per day for Suboxone®, Subutex®, or generic equivalent.

Based on the information above, will the recipient be using a larger daily dose/quantity than TennCare covers? Yes No

1. Is the prescriber a TennCare provider with a Medicaid ID? Yes No
2. Is the prescriber a single-patient contract holder for this patient? Yes No
3. Diagnosis: Treatment of opiate addiction Other: _____
4. Will buprenorphine be used for the treatment of depression or pain? Yes No
5. Is this prescription written under the "X" DEA Number such that this patient counts towards the patient limits established for individual physicians by the DATA 2000 waiver? Yes No
6. Controlled Substance Monitoring Database (CSMD) check is required on date of request. Do you attest that you comprehensively reviewed the last six (6) months in the CSMD for this patient on the date of the prior authorization request? Yes No

7. IF RECIPIENT IS BEGINNING BUPRENORPHINE MEDICATION ASSISTED THERAPY

(If continuing therapy, skip to #8)

Projected Treatment Plan *(MUST complete entire section, and then skip to question #11):*

- a) Anticipated Induction/Stabilization dose (Target < 16mg/day): _____ mg Start Date: _____
- b) Anticipated Maintenance dose (Target ≤8mg/day): _____ mg Start Date: _____
- c) Expected frequency of office visits: _____ Start Date: _____
- d) Expected frequency of counseling/psychosocial therapy visits: _____ Start Date: _____
- e) Name of Practitioner who will be providing counseling: _____

IF PATIENT HAS RECEIVED any buprenorphine product IN THE LAST SIX MONTHS, complete questions 8-11

8. Has the recipient had any concomitant opioid usage since last prior authorization approval for buprenorphine/naloxone or buprenorphine, or in previous 3 months? Yes No
- 8a. IF YES to question 8, prescriber attests that concurrent opioids have been discontinued, retrieved or destroyed. Yes No
9. Has the recipient had any concomitant benzodiazepine usage since last prior authorization approval for buprenorphine/naloxone or buprenorphine, or in previous 3 months?
- 9a. IF YES to question 9, prescriber attests that concurrent benzodiazepines have been discontinued, retrieved or destroyed.

10. Has the recipient demonstrated compliance with counseling visits since last prior authorization approval for buprenorphine/naloxone or buprenorphine, or in previous 3 months? Yes No

11. Was the most recent prior authorization approval for buprenorphine/naloxone or buprenorphine requested by a different prescriber? Yes No

IF YES, please answer 11a-11c:

11a. Prescriber Name: _____
 Contact: _____

11b. Is this prescriber in your practice group? (If yes, skip to next question. If no, go to question 11c) Yes No

11c. Have you contacted this prescriber and successfully transitioned care to your practice? Yes No

IF REQUESTING ABOVE THE QUANTITY LIMIT for buprenorphine containing products, complete questions 12-14 (Otherwise, skip to Question 15).

12. Is the recipient being treated for an initial induction/stabilization phase? Yes No

13. Is the recipient being actively treated for opioid addiction and has concomitant need for non-recurring short-term pain management? Yes No

14. Is the recipient pregnant, or has she been pregnant while receiving buprenorphine during the last 6 months? Yes No

14a. **If YES, please provide pregnancy due date:** _____

15. If requesting a non-preferred agent, please submit documentation of allergy to inactive ingredient in preferred product that is not in the requested product and any other information pertinent to this prior authorization request.

Prescriber Signature (Required)

(By signature, the Physician confirms the above information is accurate and verifiable by patient records.)

Date

Fax this form to: 1-866-434-5523

Phone: 1-866-434-5524

OptumRx will provide a response within 24 hours upon receipt.